Poll: What Viral Load Reduction Will ACH-3422 Deliver?

Achillion Pharmaceuticals (NASDAQ:ACHN)

The biotech market is eagerly awaiting phase 1 results from ACHN for their drug ACH-3422. This drug is structurally very similar to Gilead Sciences (NASDAQ:GILD) drug SOVALDI.

With the data imminent - we want to know what YOU think.  (polls are open until ACHN halts for data)

What Viral Load Reduction Will ACH-3422 Deliver?

more than 4-logs
53% (36 votes)
3.5 to 4-logs
35% (24 votes)
less than 3.5 logs
10% (7 votes)
Total votes: 67

Disclaimer Red Acre Investments is not a registered investment advisor and the views and opinions offered herein do not constitute investment advice. Investors should always conduct their own due diligence before trading. You should assume that Red Acre is trading the securities mentioned in our Red Acre Insights, generally in accordance with the views we express, although our positions may change as news evolves. We do not undertake any obligation to update our views as market conditions evolve.

Be a Smarter Biotech Investor

FREE Video Series: Mastering Biotech Binary Events

Watch Now
More Details